Proton Pump Inhibitors

From Glioblastoma Treatments
Jump to navigationJump to search
Property Information
Drug Name Proton Pump Inhibitors (e.g., Lansoprazole, Nexium)
FDA Approval Yes (for heartburn and acid-related issues)
Used for Investigational use in enhancing sensitivity of cancer cells to chemotherapy
Clinical Trial Phase Preclinical studies and observational studies in animals and humans
Clinical Trial Explanation Not specified
Common Side Effects Common PPI side effects include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness
OS without Not specified
OS with Studies suggest PPIs may improve progression-free survival in cancer treatment
PFS without 7.5 months in metastatic breast cancer patients receiving only chemotherapy
PFS with 9.5 months with 100 mg Nexium; 10.9 months with 80 mg Nexium
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation The drug being tested, a Proton Pump Inhibitor, is commonly used for heartburn and acid-related issues, and is now being tested for its potential benefits in treating cancer. Its side effects include common, non-severe symptoms like headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness. Although these can be uncomfortable, they are manageable and often temporary. Thus, we rate its toxicity a 2 out of 5. However, the drug is still under preclinical and observational studies for its use in cancer treatment, meaning its effects are not fully understood. Always consult with your physician when considering new treatments.

Notes: PPIs, commonly used for acid-related stomach issues, may suppress tumor growth by disrupting cancer cells' acid extrusion. Pre-treatment with PPIs has shown to sensitize cancer cells to cytotoxic drugs and improve treatment outcomes in preliminary studies. Further research is necessary to understand the optimal dosing and clinical efficacy in human cancer treatment.


From Ben Williams Book: Not specified

Loading comments...